Arena Pharmaceuticals (ARNA) 4.35 $ARNA
Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
PR Newswire - Mon Oct 27, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Monday, November 3, 2014, to provide a corporate update and discuss third quarter 2014 financial results. Arena will release its financial results before the NASDAQ Global Select Market opens that day.
ARNA: 4.35 (+0.16)
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 22, 7:20AM CDT
Source: Flickr user Purple Slog When it comes to the biotech sector there is perhaps no figure more important to investors or the business itself than the cash burn rate. Because most clinical-stage and early commercial stage biotech...
ZFGN: 20.52 (+1.42), OREX: 4.19 (+0.14), VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16)
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.72 (+0.08), NPSP: 28.12 (+0.80), MNTA: 11.08 (+0.11), ARNA: 4.35 (+0.16), XOMA: 4.59 (+0.17)
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 11.84 (-0.01), OHRP: 7.28 (+0.22), MNKD: 6.19 (+0.41), ARNA: 4.35 (+0.16)
Global Anti-Obesity Drugs Market
PR Newswire - Thu Oct 16, 4:07PM CDT
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -
ARNA: 4.35 (+0.16)
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine
PR Newswire - Fri Oct 10, 10:36AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was published in the October issue of Postgraduate Medicine, a peer-reviewed medical journal for physicians. In the pooled analysis, BELVIQ 10 mg twice daily, as compared to placebo and both in conjunction with diet and exercise, was associated with statistically significant weight loss and clinically relevant improvements in cardiometabolic parameters.
ARNA: 4.35 (+0.16)
3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 4.19 (+0.14), VVUS: 3.54 (+0.15), NPSP: 28.12 (+0.80), ARNA: 4.35 (+0.16), EXEL: 1.75 (+0.05)
The 1 Biotech Stock I'm Definitely Not Buying
Motley Fool Staff - Motley Fool - Tue Oct 07, 7:35AM CDT
Biotechnology stocks are notorious for roller-coaster like highs and lows, but that doesn't mean that every biotech that heads lower will climb again. Figuring out which companies are bargains and which aren't can be particularly tough in this...
DNDN: 1.06 (+0.05), AEGR: 33.69 (+1.50), ARNA: 4.35 (+0.16)
Why Is Sanofi Betting on MannKind Corporation's Afrezza?
George Budwell, The Motley Fool - Motley Fool - Mon Oct 06, 9:29AM CDT
Because the average cost of developing and bringing a new drug to market has now surpassed a whopping $5 billion, it has become commonplace for smaller pharmas to license out their first few approved products to larger companies with more resources,...
PFE: 29.09 (+0.06), LLY: 64.83 (-1.37), ABBV: 60.93 (+0.44), SNY: 48.07 (-4.75), MNKD: 6.19 (+0.41), ENTA: 44.97 (-0.72), ARNA: 4.35 (+0.16), NVS: 92.35 (+2.14)
Is VIVUS Inc. a Short Sell?
George Budwell, The Motley Fool - Motley Fool - Sat Oct 04, 12:45PM CDT
Short selling is a high risk, high reward investing strategy that requires a rock-solid investing thesis to pull off successfully. Even then, short sellers often guess wrong and pay dearly in the form of a so-called "short squeeze." Healthcare and...
OREX: 4.19 (+0.14), AUXL: 31.91 (+0.33), VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16), NVS: 92.35 (+2.14)
November 7th Options Now Available For Arena Pharmaceuticals
StockOptionsChannel.com - Thu Sep 25, 11:31AM CDT
Investors in Arena Pharmaceuticals Inc saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new November 7th contracts and...
ARNA: 4.35 (+0.16)
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
PR Newswire - Mon Sep 22, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the NewsMakers in the Biotech Industry conference on Friday, September 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time), at the Millennium Broadway Hotel in New York City.
ARNA: 4.35 (+0.16)
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
ZFGN: 20.52 (+1.42), OREX: 4.19 (+0.14), BIIB: 318.03 (-1.95), ACT: 239.03 (+0.60), ISIS: 46.43 (+0.57), AZN: 71.43 (+0.67), AUXL: 31.91 (+0.33), VVUS: 3.54 (+0.15), AMGN: 157.19 (+8.99), LLY: 64.83 (-1.37), ARNA: 4.35 (+0.16)
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
at The Street - Fri Sep 19, 9:04AM CDT
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate
ARNA: 4.35 (+0.16)
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:11AM CDT
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
CBPO: 57.78 (+1.66), BIIB: 318.03 (-1.95), CBM: 19.88 (+1.34), ARNA: 4.35 (+0.16)
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
GILD: 113.45 (+0.86), AUXL: 31.91 (+0.33), VVUS: 3.54 (+0.15), LLY: 64.83 (-1.37), ARNA: 4.35 (+0.16), DOW: 47.98 (+1.49), CELG: 105.70 (+2.60), CELGZ: 3.56 (-0.03)
Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
OREX: 4.19 (+0.14), AUXL: 31.91 (+0.33), VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16)
Hot Stock: Arena Pharmaceuticals, Shares Gain 8.7% (ARNA)
Comtex SmarTrend(R) - Thu Sep 18, 10:38AM CDT
Arena Pharmaceuticals (NASDAQ:ARNA) is one of today's best performing low-priced stocks, up 8.7% to $4.24 on 1.0x average daily volume. Thus far today, Arena Pharmaceuticals has traded 4.1 million shares, vs. average volume of 3.9 million shares per day. The stock has outperformed the Dow (8.7% to the Dow's 0.5%) and outperformed the S&P 500 (8.7% to the S&P's 0.4%) during today's trading.
ARNA: 4.35 (+0.16)
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 17, 9:51AM CDT
Arena Pharmaceuticals held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline. Below, you'll find five quotes from the call that...
VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16)
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
at The Street - Tue Sep 16, 8:48AM CDT
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
OREX: 4.19 (+0.14), VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16)
Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
PR Newswire - Mon Oct 27, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Monday, November 3, 2014, to provide a corporate update and discuss third quarter 2014 financial results. Arena will release its financial results before the NASDAQ Global Select Market opens that day.
ARNA: 4.35 (+0.16)
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 22, 7:20AM CDT
Source: Flickr user Purple Slog When it comes to the biotech sector there is perhaps no figure more important to investors or the business itself than the cash burn rate. Because most clinical-stage and early commercial stage biotech...
ZFGN: 20.52 (+1.42), OREX: 4.19 (+0.14), VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16)
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.72 (+0.08), NPSP: 28.12 (+0.80), MNTA: 11.08 (+0.11), ARNA: 4.35 (+0.16), XOMA: 4.59 (+0.17)
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 11.84 (-0.01), OHRP: 7.28 (+0.22), MNKD: 6.19 (+0.41), ARNA: 4.35 (+0.16)
Global Anti-Obesity Drugs Market
PR Newswire - Thu Oct 16, 4:07PM CDT
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -
ARNA: 4.35 (+0.16)
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine
PR Newswire - Fri Oct 10, 10:36AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was published in the October issue of Postgraduate Medicine, a peer-reviewed medical journal for physicians. In the pooled analysis, BELVIQ 10 mg twice daily, as compared to placebo and both in conjunction with diet and exercise, was associated with statistically significant weight loss and clinically relevant improvements in cardiometabolic parameters.
ARNA: 4.35 (+0.16)
3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 4.19 (+0.14), VVUS: 3.54 (+0.15), NPSP: 28.12 (+0.80), ARNA: 4.35 (+0.16), EXEL: 1.75 (+0.05)
The 1 Biotech Stock I'm Definitely Not Buying
Motley Fool Staff - Motley Fool - Tue Oct 07, 7:35AM CDT
Biotechnology stocks are notorious for roller-coaster like highs and lows, but that doesn't mean that every biotech that heads lower will climb again. Figuring out which companies are bargains and which aren't can be particularly tough in this...
DNDN: 1.06 (+0.05), AEGR: 33.69 (+1.50), ARNA: 4.35 (+0.16)
Why Is Sanofi Betting on MannKind Corporation's Afrezza?
George Budwell, The Motley Fool - Motley Fool - Mon Oct 06, 9:29AM CDT
Because the average cost of developing and bringing a new drug to market has now surpassed a whopping $5 billion, it has become commonplace for smaller pharmas to license out their first few approved products to larger companies with more resources,...
PFE: 29.09 (+0.06), LLY: 64.83 (-1.37), ABBV: 60.93 (+0.44), SNY: 48.07 (-4.75), MNKD: 6.19 (+0.41), ENTA: 44.97 (-0.72), ARNA: 4.35 (+0.16), NVS: 92.35 (+2.14)
Is VIVUS Inc. a Short Sell?
George Budwell, The Motley Fool - Motley Fool - Sat Oct 04, 12:45PM CDT
Short selling is a high risk, high reward investing strategy that requires a rock-solid investing thesis to pull off successfully. Even then, short sellers often guess wrong and pay dearly in the form of a so-called "short squeeze." Healthcare and...
OREX: 4.19 (+0.14), AUXL: 31.91 (+0.33), VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16), NVS: 92.35 (+2.14)
November 7th Options Now Available For Arena Pharmaceuticals
StockOptionsChannel.com - Thu Sep 25, 11:31AM CDT
Investors in Arena Pharmaceuticals Inc saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new November 7th contracts and...
ARNA: 4.35 (+0.16)
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
PR Newswire - Mon Sep 22, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the NewsMakers in the Biotech Industry conference on Friday, September 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time), at the Millennium Broadway Hotel in New York City.
ARNA: 4.35 (+0.16)
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
ZFGN: 20.52 (+1.42), OREX: 4.19 (+0.14), BIIB: 318.03 (-1.95), ACT: 239.03 (+0.60), ISIS: 46.43 (+0.57), AZN: 71.43 (+0.67), AUXL: 31.91 (+0.33), VVUS: 3.54 (+0.15), AMGN: 157.19 (+8.99), LLY: 64.83 (-1.37), ARNA: 4.35 (+0.16)
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
at The Street - Fri Sep 19, 9:04AM CDT
Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate
ARNA: 4.35 (+0.16)
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:11AM CDT
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
CBPO: 57.78 (+1.66), BIIB: 318.03 (-1.95), CBM: 19.88 (+1.34), ARNA: 4.35 (+0.16)
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
GILD: 113.45 (+0.86), AUXL: 31.91 (+0.33), VVUS: 3.54 (+0.15), LLY: 64.83 (-1.37), ARNA: 4.35 (+0.16), DOW: 47.98 (+1.49), CELG: 105.70 (+2.60), CELGZ: 3.56 (-0.03)
Why VIVUS, Inc. Is Today's Best Biotech Stock
Sean Williams, The Motley Fool - Motley Fool - Thu Sep 18, 12:26PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
OREX: 4.19 (+0.14), AUXL: 31.91 (+0.33), VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16)
Hot Stock: Arena Pharmaceuticals, Shares Gain 8.7% (ARNA)
Comtex SmarTrend(R) - Thu Sep 18, 10:38AM CDT
Arena Pharmaceuticals (NASDAQ:ARNA) is one of today's best performing low-priced stocks, up 8.7% to $4.24 on 1.0x average daily volume. Thus far today, Arena Pharmaceuticals has traded 4.1 million shares, vs. average volume of 3.9 million shares per day. The stock has outperformed the Dow (8.7% to the Dow's 0.5%) and outperformed the S&P 500 (8.7% to the S&P's 0.4%) during today's trading.
ARNA: 4.35 (+0.16)
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 17, 9:51AM CDT
Arena Pharmaceuticals held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline. Below, you'll find five quotes from the call that...
VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16)
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
at The Street - Tue Sep 16, 8:48AM CDT
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
OREX: 4.19 (+0.14), VVUS: 3.54 (+0.15), ARNA: 4.35 (+0.16)
